Pilot Study of Safety and Effect of Combined Intravitreal Bevacizumab and Methotrexate for Neovascular Age-Related Macular Degeneration
- 21 September 2010
- journal article
- research article
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 21 (1) , 77-82
Abstract
Purpose: To evaluate the safety and effect of combined intravitreal methotrexate and bevacizumab on choroidal neovascularization in age-related macular degeneration (AMD). Methods: Seven eyes of 7 patients (4 female; mean age 65.43±5.96 years) with choroidal neovascularization secondary to AMD were studied. Patients received intravitreal injection of methotrexate and bevacizumab and were examined every 1.5 months. Reinjections were performed with bevacizumab only. Results: Three patients had 3 months, 3 had 4.5 months, and 1 had 8 months of follow-up. Mean number of reinjections was 2.0. In all patients, best-corrected visual acuity (BCVA) improved compared to baseline. Central macular thickness (CMT) decreased in all but one patient who had no reduced visual acuity. Mean BCVA (logMAR) was 1.27±0.43 D at baseline, 1.1 ±0.38 D at week 6, and 0.93±0.31 D at month 3. Mean BCVA in 3 patients at 4.5 months was 1.1±0.15 D. There were statistically significant differences between BCVA before injection and at week 6 (p=0.017), 3 months (p=0.005), and 4.5 months (p=0.04). Mean baseline CMT was 389±177 μm, 371±154 μm at 6 weeks, and 317±108 μm at 3 months. Mean CMT in 3 patients at 4.5 months was 266±66 μm. There were no statistically significant differences between baseline CMT and after treatment. No scar formation, increase of scar, or adverse reaction to methotrexate injection were seen. Conclusions: Addition of intravitreal methotrexate to bevacizumab was safe in 7 eyes of 7 patients. It may enhance the therapeutic effect in regression of neovascularization in AMD and may reduce development of a fibrous component and disciform scar formation.Keywords
This publication has 33 references indexed in Scilit:
- Vitreous Levels of Bevacizumab and Vascular Endothelial Growth Factor-A in Patients with Choroidal NeovascularizationOphthalmology, 2008
- Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesionsBritish Journal of Ophthalmology, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ornithine decarboxylase prevents methotrexate-induced apoptosis by reducing intracellular reactive oxygen species productionApoptosis, 2005
- The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion moleculesClinical Immunology, 2005
- Two Inhibitors of DNA‐Synthesis Lead to Inhibition of Cytokine Production via a Different MechanismNucleosides, Nucleotides & Nucleic Acids, 2004
- Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2004
- Adenosine: an endogenous regulator of innate immunityTrends in Immunology, 2004
- Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degenerationAmerican Journal of Ophthalmology, 2002
- Echecs des cytostatiques en ophtalmologieKlinische Monatsblätter für Augenheilkunde, 1980